These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19300538)

  • 21. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
    Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T
    J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
    Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
    J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on bupropion in major depressive disorder.
    Dhillon S; Yang LP; Curran MP
    CNS Drugs; 2008; 22(7):613-7. PubMed ID: 18547129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
    Vis PM; van Baardewijk M; Einarson TR
    Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
    Thase ME; Entsuah AR; Rudolph RL
    Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.
    Bradwejn J; Ahokas A; Stein DJ; Salinas E; Emilien G; Whitaker T
    Br J Psychiatry; 2005 Oct; 187():352-9. PubMed ID: 16199795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
    Pollack M; Mangano R; Entsuah R; Tzanis E; Simon NM; Zhang Y
    Psychopharmacology (Berl); 2007 Oct; 194(2):233-42. PubMed ID: 17589833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM; Fernandez JL
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential involvement of NET polymorphism in serotonin/norepinephrine reuptake inhibitor response in panic disorder.
    Park HJ; Kim SK; Kang WS; Kim YJ; Cho AR; Park JK
    Nord J Psychiatry; 2016; 70(4):314-7. PubMed ID: 26508020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.
    Pae CU; Lim HK; Ajwani N; Lee C; Patkar AA
    Expert Rev Neurother; 2007 Jun; 7(6):603-15. PubMed ID: 17563244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.
    Thase ME; Ninan PT; Musgnung JJ; Trivedi MH
    Prim Care Companion CNS Disord; 2011; 13(1):. PubMed ID: 21731835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
    J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
    Silverstone PH; Entsuah R; Hackett D
    Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term goals in the management of acute and chronic anxiety disorders.
    Kjernisted KD; Bleau P
    Can J Psychiatry; 2004 Mar; 49(3 Suppl 1):51S-63S. PubMed ID: 15147036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.